PARIS and CAMBRIDGE, Mass., Oct. 04, 2017 (GLOBE NEWSWIRE) — Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks: